In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...
Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency drugs. The partnership expands Vifor Pharma’s cooperation with Fresenius ...
CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its competitor’s products.
The mining giant’s usually direct boss is thinking about raising equity. Investors are a bit dismissive. Are they ...
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.
Prima zi a acestei primăveri vine cu provocări noi, cu o vreme cam instabilă și rece care ne trimite în spații calde, unde ...
Urmăriți conferința organizată de DCNews Media Group ”Ziua Mondială a Auzului: Tratarea și prevenirea surdității în România - ...
Iron Deficiency Anemia Treatment Market Predicted to Augment and Reach over USD 22.7 billion by 2030
Treatment Market is experiencing significant growth due to the increasing prevalence of iron deficiency anemia worldwide. IDA is one of the most common nutritional deficiencies, affecting a large ...
La sfârșitul slujbei protoiereul orașului l-a rugat pe Sfântul Calnic să-i citească o rugăciune de vindecare. După citirea ...
ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback